ClindaReach®

(Clindamycin Phosphate Topical Solution USP, 1%*) Pledgets

* Equivalent to 1% (10 mg/mL) Clindamycin
Home » For Healthcare Professionals » ClindaReach®

A Topical Acne Treatment That's Within Reach

The ClindaReach® System 

ClindaReach is indicated for the treatment of acne vulgaris and is only available by prescription. The ClindaReach System provides topical clindamycin phosphate solution USP, 1% pledgets, a frequently prescribed topical antibiotic, and a unique EasyReach® applicator to make it easy to treat hard-to-reach areas, like the back.

ClindaReach

  • Allows patients to treat hard-to-reach areas themselves
  • Delivers effective treatment to targeted areas
  • Diminishes embarrassment by maintaining privacy
  • Extends patient's reach to apply prescribed topical therapy

The ClindaReach Kit includes:

 

 A generous supply in one kit

  • EasyReach Collapsible Applicator - ergonomically designed, with a multi-directional pivotal head
  • Clindamycin Pledgets -120 single use medicated pads of clindamycin phosphate solution USP, 1% 
  • 64 EasyCling Appliqués - firmly affix the pledgets or pads to the applicator arm
  • 64 EasyCleanse Unmedicated Pads - may be used for cleansing
  • Instructions for Use - to aid the patient in assembling and using the applicator

 

Important Risk Information
ClindaReach is indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate.

ClindaReach is contraindicated in individuals with hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or antibiotic-associated colitis.

Diarrhea, bloody diarrhea, colitis, and pseudomembranous colitis have been reported with the use of systemic and rarely with topical clindamycin. Discontinue use if diarrhea develops. ClindaReach should be prescribed with caution in atopic individuals.

In clinical trials, the most common adverse events were dryness, burning, itching, erythema and peeling.

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents and should be used with caution in patients receiving such agents.

ClindaReach contains alcohol that will cause burning and irritation in the event of accidental contact with sensitive areas such as the eyes and mucous membranes. Caution should be exercised when applying medication around the mouth.

Please see Full Prescribing Information.

WEB 1361 Rev E